Next Article in Journal
Cost-Effectiveness Analysis of Using Onasemnogene Abeparvocec (AVXS-101) in Spinal Muscular Atrophy Type 1 Patients
Previous Article in Journal
Technology Forecast: Advanced Therapies in Late Clinical Research, EMA Approval or Clinical Application via Hospital Exemption
 
 
Review

No Article Versions Notes Found

Back to TopTop